With a ferritin level of 261 µg/L, should iron supplementation be continued?

Iron Supplementation Should Be Discontinued at a Ferritin of 261 µg/L

With a ferritin level of 261 µg/L, iron supplementation should generally be discontinued unless there is documented functional iron deficiency (TSAT <20%) or the patient is on erythropoiesis-stimulating agents (ESAs).

Clinical Context Matters

The decision depends critically on the clinical scenario:

For General Population (Athletes, Healthy Individuals)

• Stop iron supplementation. A ferritin of 261 µg/L indicates adequate iron stores 1
• In elite athletes, iron deficiency is defined as ferritin <35 µg/L with normal hemoglobin 1
• Your patient's ferritin is well above this threshold, indicating sufficient stored iron
• Continued supplementation at this level provides no additional benefit and may expose the patient to unnecessary risks

For Chronic Kidney Disease (CKD) Patients

The approach differs based on dialysis status and ESA use:

For hemodialysis patients on ESAs:

• Continue iron if TSAT <20%, even with ferritin 200-500 ng/mL 2
• Discontinue iron if ferritin >500 ng/mL - insufficient evidence supports safety above this level 2
• At 261 µg/L, check TSAT:
  • If TSAT <20%: functional iron deficiency exists, continue iron
  • If TSAT ≥20%: adequate iron status, discontinue supplementation

For non-dialysis CKD patients:

• Target ferritin >100 ng/mL and TSAT >20% 2
• At 261 µg/L with adequate TSAT, discontinue iron

For Cancer Patients on Chemotherapy

• Iron supplementation is indicated when TSAT <20%, regardless of ferritin level (unless ferritin >800-1000 ng/mL) 3
• At ferritin 261 µg/L, check TSAT to guide decision
• If TSAT ≥20%, discontinue iron supplementation

For Heart Failure Patients

Recent evidence challenges traditional ferritin-based criteria:

• TSAT <20% is the most reliable indicator for iron deficiency and treatment benefit 4
• Ferritin 261 µg/L alone does not indicate need for iron
• Patients with ferritin <100 µg/L but normal TSAT showed no significant benefit from iron therapy 4
• Check TSAT: if ≥20%, discontinue iron; if <20%, consider continuation up to ferritin 400 µg/L

Key Pitfalls to Avoid

1. Don't rely on ferritin alone - Ferritin is an acute phase reactant and can be elevated by inflammation, infection, or chronic disease 5

2. Always check TSAT concurrently - TSAT <20% indicates functional iron deficiency even when ferritin appears adequate 5, 4

3. Recognize the upper safety limit - Most guidelines recommend caution or discontinuation when ferritin exceeds 500 ng/mL due to uncertain long-term safety 2, 6, 7

4. Context-specific thresholds matter - A ferritin of 261 µg/L means different things in different populations:

   • Excessive for healthy individuals
   • Potentially appropriate for CKD patients with low TSAT
   • Requires TSAT assessment in cancer/heart failure patients

Practical Algorithm

1. Identify the clinical population (healthy, CKD, cancer, heart failure)
2. Measure TSAT if not already done
3. Apply population-specific criteria:
   • Healthy/athletes: Stop iron (ferritin adequate)
   • CKD on ESA: Continue only if TSAT <20%
   • Cancer/heart failure: Continue only if TSAT <20%
4. Monitor for inflammation - Elevated CRP suggests ferritin may overestimate true iron stores 8

Bottom Line

At ferritin 261 µg/L, the default recommendation is to discontinue iron supplementation unless you document functional iron deficiency (TSAT <20%) in a patient with ongoing erythropoietic demands (ESA therapy, active chemotherapy, heart failure). The evidence consistently shows that TSAT is more reliable than ferritin for guiding iron therapy decisions 2, 4, and continuing iron beyond adequate stores (ferritin >200-300 µg/L with normal TSAT) offers no proven benefit while potentially increasing oxidative stress and other risks 6, 7, 9.